Loading…
← CockpitCompetitor Analysis › EVH Evolent Health Inc Class AOpen in the cockpit ↗

Evolent Health Inc Class AEVHCompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services
Momentum weak 34
Mkt cap
$445M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$8.14M
20-day average traded
Fwd P/E
9.2×
forward earnings
ROIC−WACC
-9.1 pp
WACC 7.0%
Hurdle
-1 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$3.93
1D-14.9%
1W-21.2%
1M-19.3%
3M-16.4%
6M+1.8%
YTD-1.8%
1Y+1.6%
ATR %9.0%
Beta1.02
52w lowhigh37.2% off high

What Evolent Health does

Employees: 4,200

Evolent Health at a glance

Size Evolent Health (EVH) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $445M, the 2758th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.93 on 18 Nov 2026.

Performance Over six months the shares gained 1.8%, against -23.1% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 8 in its peer set.

Growth Revenue grew 14.1% over the last twelve months (peer median +0.8%); the operating margin is -1.3% (peer median -115.5%).

Valuation It trades at 9.2× forward earnings.

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.1 points below its cost of capital (7.0% WACC).

Backlog Backlog (remaining performance obligations) was $6.00M at 30 Sep 2026, down 80% on a year earlier — 0.0 years of trailing revenue. Backlog detail →

Credit Evolent Health has 1 bond outstanding ($167M).

Short interest Short interest is 9.4% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026EVH 102Peer median 76
Six months, rebased to 100: Evolent Health against the median of its 7 peers (local-currency closes).

Evolent Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.34B$1.88B$2.55B$1.96B$1.35B
Revenue growth—-27%+30%+45%—
Gross profit$240M$284M$248M$337M$246M
EBITDA$81.1M$111M$126M$154M$95.3M
Net income-$508M-$535M-$61.6M-$113M-$18.7M
Free cash flow$36.7M$4.75M-$6.13M$114M-$49.9M
Capital expenditure$28.2M$34.1M$24.9M$28.7M$47.5M
Total debt$973M$990M$904M$823M$476M

Quarterly statements and history in the cockpit →

Evolent Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%-10%0%+10%OCSTECXEVTANLSBCOABISLNEVH6-month return →1-month return →
Up and to the right = strong over both horizons. Evolent Health is the large dot.

Capital: growth delivered against growth the price implies

-25%0%+25%+50%0%50%SBCOABIEVHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Evolent Health is the large dot.

Evolent Health competitors and peer comparison

How Evolent Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Evolent Health against its 7 peers (data as of 18 Nov 2026)
MeasureEVHPeer medianRank in peer set
1-month return-19.3%+0.2%lowest of 8
6-month return+1.8%-23.1%4th highest of 8
Distance from 52-week high-37.2%-46.8%4th highest of 8
Revenue growth (TTM)+14.1%+0.8%2nd highest of 5
Operating margin-1.3%-115.5%2nd highest of 6
Forward P/E9.2×n/a—
Growth the price implies (Req g, 7 yrs)14.0%n/a—
Growth delivered (Del g)+15.2%n/a—
Hurdle (Req g minus delivered)-1.2 ppn/a—
ROIC minus cost of capital-9.1 pp-18.0 pp2nd highest of 4
Net debt / EBITDA10.1×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Evolent Health EVHUnited States$445M+2%+14%-1%9.2×14.0%+15.2%
Oculis OCSUnited States$456M-74%n/an/an/an/an/a
Tectonic Therapeutic TECXUnited States$420M-27%n/an/an/an/an/a
Evotec EVT.DEGermany$532M-46%-5%-15%n/an/an/a
Adlai Nortye Ltd. Sponsored ADR ANLUnited States$610M-23%n/a-134%n/an/an/a
SBC Medical SBCUnited States$645M+94%+7%40%11.7×-15.7%+6.7%
OmniAb OABIUnited States$741M+97%+91%-116%n/a60.6%-31.9%
Silence Therapeutics PLC Sponsored ADR SLNUnited States$1.23B+244%-98%-11,920%n/an/an/a

Evolent Health bonds and credit

Evolent Health has 1 bond outstanding with $167M face value.

Every bond, yield and spread in the cockpit →

Evolent Health backlog

Evolent Health reported $6.00M of remaining performance obligations at 30 Sep 2026, down 80% from a year earlier and down 42% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 0.99.

Questions

Which companies are Evolent Health's closest peers?
The cockpit's peer set: Oculis (OCS), Tectonic Therapeutic (TECX), Evotec (EVT.DE), Adlai Nortye Ltd. Sponsored ADR (ANL), SBC Medical (SBC), OmniAb (OABI), Silence Therapeutics PLC Sponsored ADR (SLN).
How has Evolent Health stock performed?
Over six months to 18 Nov 2026 the shares returned +1.8% against -23.1% for the median peer; over one year +1.6%.
What is Evolent Health's backlog?
Evolent Health's remaining performance obligations (contracted revenue not yet recognised) were $6.00M at 30 Sep 2026, -80% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.